Key takeaways for Washington
- • No GLP-1 is FDA-labeled for prediabetes — use is off-label.
- • Eligibility may still apply if BMI 30+ or 27+ with comorbidity (Wegovy/Zepbound).
- • Roughly 80-95% of prediabetic adults revert to normoglycemia in major trials.
- • Apple Health coverage rules apply for Prediabetes patients in Washington — see Medicaid section below.
- • 16 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Prediabetes
No GLP-1 drug carries an FDA prediabetes indication. However, in obese prediabetic adults, Wegovy and Zepbound are approved on the basis of BMI/comorbidity criteria, and both have been shown in trial post-hoc analyses to convert prediabetes back to normoglycemia in the majority of treated patients. Evidence grade: B (extrapolation from RCT subgroups). Lifestyle therapy and metformin remain first-line per ADA. GLP-1 use specifically for prediabetes is off-label and should be discussed with a physician.
Washington-specific context
Washington has telehealth access concentrated in Seattle, Spokane, Tacoma metros, with additional reach to Vancouver and Bellevue. UW Medicine, Providence, Swedish Medical Center, Virginia Mason is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.doh.wa.gov.
Washingtontelehealth & pricing rules
- • Washington requires a live video consultation before a GLP-1 prescription.
- • Washington allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Washington: ~$308/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.